Telix Resubmits Brain Cancer Drug to FDA

Australian biotech firm Telix Pharmaceuticals resubmits its NDA to the U.S. FDA for TLX101-Px, branded Pixclara, a promising brain cancer imaging agent that could revolutionize diagnostics. This move follows prior feedback, showing persistence against bureaucratic red tape that often stalls life-saving innovations. If approved, it empowers doctors with better tools to fight glioblastoma, cutting government overreach in healthcare by speeding targeted treatments. Read more about this...